Prexa Pharma raises $3.2M to target ADHD, depression, Parkinson's

Boston’s Prexa Pharmaceuticals Inc. has brought in $3.25 million of a $7 million equity round, according to a filing with the U.S. Securities and Exchange Commission [1].

The company, founded in 2006 according to its website [2], is developing small molecule monoamine reuptake inhibitors focused on enhancing dopamine activity with the goal of improving on treatments for central nervous system disorders ADHD, depression and Parkinson’s disease.

SOURCE [3]